Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer.
Alderdice M, Craig SG, Humphries MP, Gilmore A, Johnston N, Bingham V, Coyle V, Senevirathne S, Longley DB, Loughrey MB, McQuaid S, James JA, Salto-Tellez M, Lawler M, McArt DG. Alderdice M, et al. NAR Genom Bioinform. 2021 Apr 20;3(2):lqab016. doi: 10.1093/nargab/lqab016. eCollection 2021 Jun. NAR Genom Bioinform. 2021. PMID: 33928242 Free PMC article.
Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.
Craig SG, Humphries MP, Alderdice M, Bingham V, Richman SD, Loughrey MB, Coleman HG, Viratham-Pulsawatdi A, McCombe K, Murray GI, Blake A, Domingo E, Robineau J, Brown L, Fisher D, Seymour MT, Quirke P, Bankhead P, McQuaid S, Lawler M, McArt DG, Maughan TS, James JA, Salto-Tellez M. Craig SG, et al. Among authors: alderdice m. Br J Cancer. 2020 Oct;123(8):1280-1288. doi: 10.1038/s41416-020-0985-5. Epub 2020 Jul 20. Br J Cancer. 2020. PMID: 32684627 Free PMC article.
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.
Alvi MA, McArt DG, Kelly P, Fuchs MA, Alderdice M, McCabe CM, Bingham V, McGready C, Tripathi S, Emmert-Streib F, Loughrey MB, McQuaid S, Maxwell P, Hamilton PW, Turkington R, James JA, Wilson RH, Salto-Tellez M. Alvi MA, et al. Among authors: alderdice m. Oncotarget. 2015 Aug 28;6(25):20863-74. doi: 10.18632/oncotarget.4576. Oncotarget. 2015. PMID: 26315110 Free PMC article.
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Alderdice M, Dunne PD, Cole AJ, O'Reilly PG, McArt DG, Bingham V, Fuchs MA, McQuaid S, Loughrey MB, Murray GI, Samuel LM, Lawler M, Wilson RH, Salto-Tellez M, Coyle VM. Alderdice M, et al. Mod Pathol. 2017 Sep;30(9):1287-1298. doi: 10.1038/modpathol.2017.47. Epub 2017 Jun 16. Mod Pathol. 2017. PMID: 28621318 Free article.
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M. Dunne PD, et al. Among authors: alderdice m. Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568398 Free PMC article.
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group. Buzdar A, et al. Among authors: alderdice m. Breast Cancer Res Treat. 2002 May;73(2):161-75. doi: 10.1023/a:1015229630260. Breast Cancer Res Treat. 2002. PMID: 12088118 Clinical Trial.
26 results